Anti-PD-L1/Anti-TGF-beta Bifunctional Fusion Protein TQB2858 clinical trials
How each study uses Anti-PD-L1/Anti-TGF-beta Bifunctional Fusion Protein TQB2858 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PD-L1/Anti-TGF-beta Bifunctional Fusion Protein TQB2858 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- TQB2858 injection
- 7
Studies by the year they started
7 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2021 | 3 |
| 2022 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (5) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Anti-PD-L1/Anti-TGF-beta Bifunctional Fusion Protein TQB2858 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant TumorsRecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04805060Written as TQB2858 injectionHow we know
- Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade SarcomaTerminatedPhase 2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT05262101Written as TQB2858 injectionHow we know
- Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant TumorsTerminatedPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05154630Written as TQB2858 injectionHow we know
- A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic CarcinomaTerminatedPhase 1Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT05193604Written as TQB2858 injectionHow we know
- To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal CancerStatus unknownPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05198531Written as TQB2858 InjectionHow we know
- A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced MalignancyStatus unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05068921Written as TQB2858 injectionHow we know
- A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial CarcinomaStatus unknownPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05121363Written as TQB2858 injectionHow we know